Todos Medical Ltd.

Equities

TOMDF

IL0011392375

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:07:29 2024-04-25 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-99.50%

2023	Todos Announces Notice of Allowance from Uspto for Patent Application Covering Use of Compositions in Tollovid?? and Tollovir?? Ingredients	CI
2023	Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics	CI

Todos Medical Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 16, 2022 at 04:44 pm EDT

Todos Medical Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 2.2 million compared to USD 5.03 million a year ago. Net loss was USD 7.59 million compared to USD 17.56 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.04 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.04 a year ago.

Latest news about Todos Medical Ltd.

Todos Announces Notice of Allowance from Uspto for Patent Application Covering Use of Compositions in Tollovid?? and Tollovir?? Ingredients	23-08-30	CI
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics	23-02-14	CI
Todos Medical Ltd. Enters into Exclusive Worldwide Automated Retail Supply Agreement with Smart Automated Retail Network	22-11-16	CI
Todos Medical Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Todos Medical Terminates Tollovid Products License & Distribution Agreement with T-Cell Protect Hellas S.A	22-11-10	CI
Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for Monkeypox PCR Test to US FDA	22-10-14	CI
Todos Medical Announces USPTO Trademark Notice of Allowance for 3Cl Protease Biomarker Diagnostics Tollotest™	22-09-27	CI
Todos Medical Ltd. Enters into $50 Million Contract to Supply Tollovid(TM) and CBD Products to Retail Distributor Company Nerd Hemp	22-09-22	CI
Todos Medical Initiates Validation Plan for PCR-Based Polio Testing at CLIA/Cap Laboratory Provista Diagnostics	22-09-14	CI
Todos Medical, Ltd. Signs to Agreement with Its 3CL Protease Biology Theranostics Partner NLC Pharma, Ltd	22-09-12	CI
Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production	22-08-31	CI
Todos Medical Announces Saliva-Only Monkeypox Testing At Clia/Cap Clinical Lab Provista Diagnostics	22-08-26	CI
Todos Medical, Ltd. Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series	22-08-25	CI
Todos Medical, Ltd Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women	22-08-23	CI
Todos Medical Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-22	CI
Todos Medical Ltd. Completes Trial Design for Tollovid™ Long Covid Clinical Study in Adults	22-08-11	CI
Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels At CLIA/CAP Lab Provista Diagnostics	22-08-10	CI
Todos Medical, Ltd. Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics	22-08-08	CI
Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics	22-08-05	CI
Todos Medical Ltd. Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients	22-06-30	CI
Todos Medical Releases Preliminary Data from Irb-Waived Tollovid® Market Research Study in Acute and Long Covid	22-06-23	CI
Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff	22-06-22	CI
Todos Medical Ltd. Completes Validation of 27 Pathogen UTI PCR Panel at its CLIA/CAP Laboratory Provista Diagnostics	22-06-13	CI
Todos Medical, Ltd. Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial Vs. Amyloid PET	22-06-03	CI
Todos Medical Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI

Chart Todos Medical Ltd.

Duration

Period

More charts

Company Profile

Todos Medical Ltd is a Israel-based clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer. The Companys Total Biochemical Infrared Analysis (TBIA) platform, represents a method for cancer screening of solid tumors using peripheral blood spectroscopy analysis. The process involves observing the immune systemâs response to tumor presence. TBIA analyzes the entire biochemical signatures spectrum including proteins, lipids, nucleic acids and carbohydrates of effected immune cells from peripheral blood, using infrared spectroscopy.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
TODOS MEDICAL LTD.	-99.50%	3.32K
EXACT SCIENCES CORPORATION	-20.45%	10.82B
IOVANCE BIOTHERAPEUTICS, INC.	+43.17%	3.25B
GUARDANT HEALTH, INC.	-35.86%	2.11B
BGI GENOMICS CO., LTD.	-17.21%	2.08B
VERACYTE, INC.	-29.81%	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.56%	1.02B
SEEGENE, INC.	-4.37%	733M
CAREDX, INC	-37.00%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.94%	383M

Bio Diagnostics & Testing